Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pain drug could make eye surgery recovery safer and faster

NCT ID NCT07269106

Symptom relief Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new painkiller called Anrikefon in 204 adults having eye surgery under general anesthesia. Researchers want to see if it controls pain as well as the standard drug nalbuphine, but with fewer side effects like drowsiness. Participants get one dose during surgery and are monitored for pain, side effects, and recovery speed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Anrikefon
What this could lead to
If it works, this could offer a safer painkiller for eye surgery with fewer side effects like dizziness or sedation.
What could go wrong
This is a mid-stage trial with only 204 people, so results may not apply to everyone. The drug might not work as well as expected or could still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 204 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Scheduled for ophthalmic surgery under general anesthesia. * Aged 18 to 70 years. * With American Society of Anesthesiologists (ASA) physical status I to III. * Body mass index (BMI) between 18 and 30 kg/m² * Agree to participate in the trial and provide written informed consent. Exclusion Criteria: * History of cardiovascular or cerebrovascular events within the past 6 months, including unstable angina, ischemic myocardial infarction, or heart failure; or current presence of uncontrolled hypertension (\>180/110 mmHg), aneurysm, or severe cardiac arrhythmia. * Severe respiratory diseases such as pulmonary fibrosis, severe pulmonary abscess, cor pulmonale, or advanced chronic obstructive pulmonary disease (COPD). * Significant neurological disorders such as brain injury or seizures, as well as severe psychiatric illnesses. * Known allergy to kappa opioid receptor agonists or to general anesthetic agents used in this study. * Current peptic ulcer disease, gastrointestinal bleeding, or known hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs), such as flurbiprofen axetil or paracetamol. * Prior use of opioid or non-opioid analgesics, with the last administration occurring within five half-life periods of the drug. * Continuous use of opioid analgesics for more than 10 days within the 3 months prior to screening. * Use of drugs with unknown half-life periods that may affect analgesic efficacy within 14 days before randomization. * History of major surgery within the past 3 months that may interfere with postoperative pain assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ophthalmic surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ophthalmic surgery Opioid analgesia Postoperative pain management

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Eye & ENT Hospital of Fudan University

    NOT_YET_RECRUITING

    Shanghai, 200031, China

  • The Affiliated Hospital of Yunnan University

    NOT_YET_RECRUITING

    Kunming, Yunnan, 650000, China

  • Zhongshan Ophthalmic Center, Sun Yat-Sen University

    RECRUITING

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.